Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

25
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,910094,1100
Operating income (EBITDA)--68,4-66,9-52,7-47,0-30,6
Operating profit (EBIT)-73,3-73,0-71,5-55,8-75,7-73,4
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-56,4-79,7-78,7
EPS ( $)-0,95-0,87-0,83-0,66-0,89-0,86
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514283,693,157,8
Operating income (EBITDA)--68,4-66,9-52,7-47,0-30,6
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,187,947,755,00
Book Value Per Share (BVPS)-1,44 $0,88 $0,46 $1,49 $-
Cash Flow per Share--0,72 $-0,63 $-0,63 $-0,43 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 678 M$ -
Entreprise Value (EV) 594 M$ 585 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 6,76x 7,20x
EV / Revenue 5,93x 6,21x
EV / EBITDA -11,3x -12,4x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 17,1x 5,28x
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -55,7% -80,5%
operating Leverage (Delta EBIT / Delta Sales) 0,33x -5,79x
Net Margin (Net Profit / Revenue) -56,2% -84,8%
ROA (Net Profit / Asset) -44,6% -
ROE (Net Profit / Equities) -109% -188%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   7,92% 8,24%
Cash Flow / Sales (Taux d'autofinancement) -54,5% -39,1%
Capital Intensity (Assets / Sales) 1,26x -
Financial Leverage (Net Debt / EBITDA) 1,59x 1,98x
EPS & Dividend
Dynamic quotes  
ON
| OFF